Reports of myocarditis and pericarditis following mRNA COVID-19 vaccines: A systematic review of spontaneously reported data from the UK, Europe, and the US and of the literature

Samantha Lane* [1,2]

[1] Drug Safety Research Unit, Southampton, Hampshire, UK

[2] School of Pharmacy and Biomedical Sciences, University of Portsmouth, Hampshire, UK

ORCiD: 0000-0001-7532-1149

Alison Yeomans[1]

[1]Drug Safety Research Unit, Southampton, Hampshire, UK

Saad Shakir [1,2]

[1] Drug Safety Research Unit, Southampton, Hampshire, UK

[2] School of Pharmacy and Biomedical Sciences, University of Portsmouth, Hampshire, UK

*Correspondence to:

Miss Samantha Lane

Samantha.Lane@dsru.org

Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, Hampshire, SO31 1AA

Word count: 4828 (excluding tables)

Number of tables: 5

Number of figures: 1

Abstract

Objectives: To bring together spontaneously reported data from around the world to estimate the reporting rate in different countries and better understand the risk factors for myocarditis and pericarditis following exposure to COVID-19 mRNA vaccines.

Design: Systematic review of the literature and systematic review of spontaneously reported data from the United Kingdom (UK), United States (US), and European Union/European Economic Area (EU/EEA).

Data sources: Spontaneously reported data for COVID-19 Vaccine Pfizer/BioNTech (Comirnaty) and COVID-19 Vaccine Moderna (Spikevax) were obtained using outputs from the UK's Yellow Card scheme (covering the period 09/12/2020 – 20/10/2021), the Vaccine Adverse Event Reporting System (VAERS; US; covering the period 23/08/2021 – 21/10/2021), and EudraVigilance (EU/EEA; covering the period 21/12/2020 – 21/10/2021). Systematic searches of PubMed and Embase literature databases were performed with a datalock point of 11 October 2021.

Eligibility criteria: All publicly available spontaneous reporting data from the three regions of interest were included. Data on events labelled "Myocarditis" and "Pericarditis" were included. No restrictions on age or gender were applied. For the systematic literature review, all pharmacoepidemiological studies of observational design investigating myocarditis and pericarditis following mRNA COVID-19 vaccines identified by our search were included. No restrictions on language or date were applied. Pre-print manuscripts were included if no peer-reviewed version was available. Studies of non-observational design, case reports, and case series were excluded. Study quality was assessed using relevant Critical Appraisal Skills Programme (CASP) tools. All studies were considered of sufficient quality for inclusion.

Data extraction and synthesis: One researcher extracted data from spontaneous reporting systems and published pharmacoepidemiological studies. Spontaneously reported events of myocarditis and pericarditis were presented for each individual data source, and stratified by vaccine, age, sex, and dose where this information was available. Vaccination data were obtained to the same date, and reporting rates were calculated for the events of myocarditis and pericarditis for each population of interest. For published pharmacoepidemiological studies, the study design, participant characteristics, and study results were tabulated.

Results: Overall, there were 435 reports of myocarditis and 327 reports of pericarditis reported to the UK's Yellow Card scheme up to 20 October 2021. To 21 October 2021, in the US, 1936 reports of myocarditis and 1271 reports of pericarditis had been submitted to VAERS; there had been 2924 reports of myocarditis and 1855 reports of pericarditis submitted to EudraVigilance to the same date. Most reports (73.3%) had been submitted following Comirnaty (Pfizer/BioNTech). Males represented 74.9% of reports of myocarditis and 56.9% of pericarditis overall (for US and EU/EEA populations only), and the majority of reports concerned vaccinees ages under 40 years. Reports were more frequent following the second dose of mRNA COVID-19 vaccine. Reporting rates of myocarditis and pericarditis were consistent between the data sources. Seven pharmacoepidemiological studies were included; results of these studies were largely consistent with results of our spontaneous report analyses.

Conclusions: This study provides evidence that younger vaccinees more frequently report myocarditis and pericarditis following mRNA COVID-19 vaccines compared with older vaccinees. These events had mild clinical course followed by full recovery in most cases. Results from published literature supported the results of our analyses.

Strengths and Limitations of the Study

- This is the first study to bring together spontaneously reported data from the United Kingdom, United States, and Europe on myocarditis and pericarditis following mRNA COVID-19 vaccines.
- Results from this study provide evidence on the frequency of reported events of myocarditis and pericarditis following mRNA vaccines in different age groups, and by sex and vaccine dose. Analyses of spontaneous reports were consolidated with results of published literature, identified by systematic review.
- Results may have been influenced by biases including different vaccination policies in each region examined, and publicity on events of myocarditis and pericarditis following mRNA vaccines.
- The study relied on outputs from spontaneous reporting systems in which the level of detail differed between the systems examined; furthermore, it is not possible to estimate incidence rates using spontaneous reports due to the lack of data on the exposed population, and there is no unvaccinated comparison group.
- There is an urgent need for further pharmacoepidemiological studies to be conducted to provide more accurate estimates of the frequency, clinical course, long term outcome, effects of treatment and impact on quality of life, to address many of the limitations of spontaneous reporting.

1.0 Introduction

Myocarditis and pericarditis (inflammation of the heart muscle and inflammation of the sac that surrounds the heart, respectively) have recently been recognised as very rare adverse effects of messenger RNA (mRNA) vaccines against coronavirus disease 2019 (COVID-19), manufactured by Pfizer/BioNTech and Moderna (1-4). In the general population, myocarditis is diagnosed in approximately ten to 20 individuals per 100,000 per year, and has been demonstrated as more commonly diagnosed in males and in younger age groups (mostly in vaccinees aged under 40 years) (5). In the general population of the United Kingdom (UK) in 2020, the rate of myocarditis was 11.05 (9.74-12.48) cases per 100,000 person-years (6). Symptoms indicative of myocarditis or pericarditis after COVID-19 vaccine include: new onset and persisting chest pain, shortness of breath, or palpitations following vaccination (7). The United States' (US) Centers for Disease Control and Prevention (CDC) advise that medical attention is sought if symptom onset is within one week of receiving an mRNA vaccine (1). Where possible, suspected cases should be evaluated, provided guidance, and be followed up with a cardiologist [3]. It is important that differential diagnoses, including COVID-19 infection, are considered and ruled out (7).

The signal of myocarditis and pericarditis following mRNA vaccines was first identified in Israel in May 2021, where there had been 148 cases of myocarditis reported within 30 days of vaccination, with the majority of these cases (n=121) reported after the second dose (4). At this time, Israel had rapidly rolled out the Pfizer/BioNTech mRNA COVID-19 vaccine (Comirnaty) to its population and was amongst the first countries to provide widespread COVID-19 vaccines to young adults (4, 8). The Israeli Ministry of Health appointed an epidemiological team to investigate the possible link between these cases of myocarditis and the vaccine (4). Results from this assessment were that there was a possible link between the second vaccine dose and the onset of myocarditis among young men aged 16 to 30 (4). This link was found to be stronger amongst 16-19 year olds compared with other age groups (4).

After the signal initially emerged in Israel, further cases of myocarditis and pericarditis following mRNA COVID-19 vaccines were reported in multiple countries (7). The World Health Organisation's (WHO) Global Advisory Committee on Vaccine Safety (GACVS) issued a statement on 9 July 2021, outlining the emerging signal of myocarditis and pericarditis (7). On 19 July 2021, a Dear Healthcare Provider letter was issued by the European Medicines Agency, to bring clinicians' attention to this possible adverse event of vaccination (2). Furthermore, the product information for both mRNA vaccines was updated to include myocarditis and pericarditis as an adverse event of unknown frequency in the UK, Europe, and the US (9-15). Data suggest that the immediate course of myocarditis and pericarditis following vaccination is generally mild and responds to treatment such as rest, and nonsteroidal anti-inflammatory medications (7). In Israel it was determined that vaccinees who develop myocarditis or pericarditis often require short-term hospitalisation (4). Although most cases appear to have mild severity, further follow-up of cases is ongoing to determine the long term outcomes of myocarditis and pericarditis following mRNA vaccines (1, 7).

As vaccine policies in the UK, US, and EEA progress into their advanced stages, the focus has shifted towards vaccinating adolescents and young adults, with both Pfizer/BioNTech and Moderna vaccines (Comirnaty and Spikevax, respectively) authorised for use in

children over the age of 12 years in each of these regions (with the exception of Spikevax in the US) (10-15). In the UK, all children and adolescents aged 12 to 17 years have been offered a first dose of COVID-19 vaccine (16). For those who are clinically extremely vulnerable, live with somebody who is clinically extremely vulnerable, or turn 18 years of age in the following three months, a second dose is offered (16, 17). In the EU, Comirnaty was initially approved for use in children and adolescents aged 12 and over in May 2021 and Spikevax was authorised for this age group in July 2021 (18). As of November 2021, both mRNA vaccines are under review to extend their use for children aged five years and older (19, 20). Meanwhile in the US, Comirnaty has been approved for use in children aged five and over (21).

From the data available, young men and adolescent males appear at higher risk of myocarditis or pericarditis following exposure to mRNA vaccines, with cases occurring within a few days of vaccination (7). The event appears to occur more frequently following the second dose of the vaccine. Individual regulatory authorities continue to monitor the events of myocarditis and pericarditis in their own spontaneous reporting systems (2, 3, 22). The clinical course is typically mild and self-limiting, with most cases making a full recovery (23). While the majority of vaccinees experiencing myocarditis or pericarditis after mRNA vaccination are below the age of 40, older patients have also developed these events. It is currently not known at what frequency myocarditis and pericarditis may occur following a third dose of COVID-19 vaccine. Due to the characteristics of the population offered a third dose at present (clinically extremely vulnerable), it is likely that increasing numbers of vaccinees offered a third dose will have pre-existing health conditions. These people were vaccinated early in the programme, and thus are likely to have received an adenovirus vector vaccine for their first two doses. Vaccinees receiving a third dose of COVID-19 vaccine need to be monitored intensively to determine the frequency and severity of myocarditis and pericarditis following mRNA COVID-19 vaccines, and to identify any newly emerging safety concerns.

We aimed to bring together spontaneously reported data from several countries to better understand risk factors for myocarditis and pericarditis following exposure to COVID-19 mRNA vaccines. This is important because young adults are or will be receiving mRNA COVID-19 vaccinations in the UK and EU. Also, only mRNA vaccines have been authorised for use in children older than 12 years. Third doses of COVID-19 vaccines have also begun to be administered. The results from this study will inform risk of myocarditis and pericarditis following mRNA vaccines in each subpopulation.

2.0 Materials and Methods

Spontaneous reporting outputs of the UK (Yellow Card scheme), US (Vaccine Adverse Event Reporting System [VAERS] via the CDC Wonder online tool), and European Economic Area ([EEA] EudraVigilance) were used to estimate the frequency of reported cases of myocarditis and pericarditis following COVID-19 Vaccine Pfizer/BioNTech (Comirnaty) and COVID-19 Vaccine Moderna (Spikevax) (24-26). All cases of myocarditis and pericarditis which had been spontaneously reported to these systems between the date of vaccine launch and the datalock point were counted. Cases were stratified by age, sex, and vaccine dose where these data were available.

Data on events labelled “Myocarditis” and “Pericarditis” were obtained from each database. The datalock point was 21 October 2021 for VAERS and EudraVigilance, and 20

October 2021 for the Yellow Card scheme. Data from the Yellow Card scheme is released weekly, with data up to 20 October 2021 the closest release to the 21 October 2021 datalock point used for VAERS and EudraVigilance.

The number of vaccinated individuals per vaccine brand in the UK, US, and EEA were obtained from the websites of the MHRA, the CDC in the US, and the European Centre for Disease Prevention and Control (ECDC) up to the date closest to the datalock point for ADR spontaneous reports (3, 27, 28). Reporting rates of myocarditis and pericarditis per million vaccines administered were calculated for those who had received at least one dose of each vaccine brand.

2.1 Literature Review

A systematic literature review was conducted using PubMed/Medline and Embase literature databases. No review protocol was prepared.

The datalock point was 11 October 2021. Studies were included if they were observational in design (excluding case reports and case series), and involved at least one patient who experienced myocarditis, pericarditis, or myopericarditis following any mRNA COVID-19 vaccine (any case definition was accepted). Pre-print manuscripts were included if no peer-reviewed version was available. Studies of other designs and studies investigating other vaccines were excluded. Studies investigating cardiac effects of SARS-CoV-2 infection were excluded. No restrictions on language or date were applied.

The search terms used were:

(myocarditis OR pericarditis OR myopericarditis) AND (covid-19) AND (vaccine)

Data were extracted for study design, study period, vaccine of interest, population, number of cases of myocarditis or pericarditis, and where specified the percentage of cases who were male, age, and the vaccine dose after which the event occurred. One reviewer extracted data. These data were tabulated.

Study quality was assessed by one reviewer, using the relevant Critical Appraisal Skills Programme (CASP) tool (criteria not presented) (33). Each checklist covers a different study design and contains a series of questions to critically appraise the research.

2.2 Updating the Review

This is intended to be a “living” systematic review. We will provide an update when new information or publications are released which significantly impacts our conclusions. At this time, systematic literature searches using the above search terms and criteria will be run and spontaneously reported data will be updated.

Results and conclusions will be updated if new pharmacoepidemiological evidence has been released. Due to the nature of spontaneous reporting (i.e. events counts change daily), this data will be updated at the same time as the systematic literature review. Updates to the results and conclusions will be submitted as letter to the editor communications, to be used as an addendum to the original manuscript. Each update will cite the original manuscript and previously published updates.

2.3 Patient and Public Involvement

Patients and the public were not consulted during this study.

3.0 Results

Overall, across the three spontaneous reporting databases examined, there were a total of 5295 events of myocarditis and 3453 reports of pericarditis submitted to the regulators up to 21 October 2021. Of the reported events of myocarditis, 3883 (73.3%) concerned Comirnaty, whereas 75.9% of all pericarditis reports (n=2620 of 3453 reports) followed the Comirnaty vaccine.

Sex and age data were only available for the VAERS and EudraVigilance populations (Figure 1). Age was skewed towards younger vaccinees for both myocarditis and pericarditis following Comirnaty and Spikevax for the VAERS and EudraVigilance populations (Figure 1). In these populations, males represented 74.9% (n=3641 of 4860) of all myocarditis reports and 56.9% (n=1778 of 3126) of all pericarditis reports.

3.1 United Kingdom

Data reported to MHRA's Yellow Card scheme was available from the data of each vaccine's authorisation to 20 October 2021 (3). Overall, 435 reports of myocarditis and 327 reports of pericarditis had been submitted to the Yellow Card scheme from the date of vaccine launch to 20 October 2021. Of these, there were 350 reported myocarditis events and 274 pericarditis events reported to Yellow Card scheme up to and including 20 October 2021 following Comirnaty (Table 1). Two of these events were reported to have a fatal outcome (n=1 each for myocarditis and pericarditis). For Spikevax, 85 reports of myocarditis and 53 reports of pericarditis had been submitted to the Yellow Card scheme up to 20 October 2021; none of these events had a fatal outcome (Table 1). No data was available on the age or sex of those reporting events, or on which dose of the vaccine each event occurred.

As of 20 October 2021, it was estimated that 23.2 million first doses and 20.1 million second doses of Comirnaty had been administered in the UK (3). Therefore, there were approximately 15.09 cases of myocarditis and 11.81 cases of pericarditis per million vaccinees who had received at least one dose of Comirnaty. To the same date, approximately 1.5 million first doses and 1.3 million second doses of Spikevax had also been administered (3). Therefore, of those who had received at least one dose of Spikevax in the UK, 56.67 cases of myocarditis and 40.77 cases of pericarditis had been reported per million vaccinated.

3.2 United States

To 21 October 2021, there had been 1314 events of myocarditis reported following the Comirnaty overall (Table 2). Of these, 1001 (76.18%) had occurred in males (Table 2). There was evidence of a higher frequency of reports for younger age groups amongst both males and females, with a decreasing number of reports with increasing age (Table 2). While pericarditis was again more frequently reported in males (n=539; 65.97% of 817 reported events) following Comirnaty, for vaccinees over 40 years of age the pattern was less pronounced (Table 2). For Spikevax, similar trends were observed. Of the 622 events of myocarditis reported to VAERS following Spikevax, 73.47% (n=457) occurred in males, with more frequent reports in younger age groups (Table 2). Similarly, 58.81% of the

total 454 reported pericarditis events occurred in males, however for pericarditis the trend in age was less distinct (Table 2).

The majority of both myocarditis and pericarditis reported events occurred after the second dose of Comirnaty (Table 3a) and Spikevax (Table 3b). For Comirnaty, of the total 1314 reported events of myocarditis, 771 (58.68%) were reported following the second dose while 280 (21.31%) were reported after a single dose of the vaccine (Table 3a). Similarly, 53.00% of events of pericarditis were reported following two doses of Comirnaty (n=433 of 817 reported events; Table 3a). For Spikevax, 291 of 622 (46.78%) reported events of myocarditis and 229 of the 454 (50.44%) reported events of pericarditis occurred following two doses of the vaccine (Table 3b). A small number of reports of myocarditis and pericarditis had been reported following a third dose for both vaccines (Tables 3a and 3b).

In the US, there had been 104.98 million vaccinees who had received the full two-dose regimen of Comirnaty (27); therefore, there were 12.52 cases of myocarditis reported per million and 7.78 cases of pericarditis per million fully vaccinated individuals. There had been 69.70 million people fully vaccinated with Spikevax (27); therefore, there were 8.92 cases of myocarditis reported per million fully vaccinated Spikevax recipients and 6.51 cases of pericarditis per million fully vaccinated Spikevax vaccinees.

3.3 European Economic Area

To 21 October 2021, there had been a total of 2219 reports of myocarditis and 1529 reports of pericarditis to EurdraVigilance from the EEA, following Comirnaty. Following Spikevax, there were 705 reports of myocarditis and 326 reports of pericarditis submitted to EudraVigilance up to 21 October 2021 (Table 4). For both mRNA vaccines, 76.03% of the reported myocarditis events from the EEA were reported in males. Meanwhile, 52.40% of pericarditis events reported to EudraVigilance following mRNA vaccines were reported in males.

There were 15 reports of myocarditis and five reports of pericarditis which had a fatal outcome following Comirnaty, and four fatal reports of myocarditis and one of pericarditis following Spikevax. Most of these fatal events were in males (16 of 25 reports with fatal outcomes overall; 64.00%).

To the week ending 17 October 2021, approximately 267.48 million first doses of Comirnaty had been administered throughout the EU and EEA (28). Therefore, there were approximately 8.30 cases of myocarditis and 5.72 cases of pericarditis reported per million vaccinees who had received at least one dose of Comirnaty. Spikevax had been administered to considerably fewer vaccinees up to the same date, with a total 40.02 million first doses given in the European Union and EEA (28). There were 17.62 cases of myocarditis and 8.15 cases of pericarditis per million vaccinees who had received at least one dose of Spikevax.

3.4 Systematic literature review

There were 253 studies identified by the search within PubMed/Medline and Embase databases. Following de-duplication of manuscripts there were 175 papers which underwent screening. After applying exclusion criteria, seven published epidemiological studies were included in the systematic literature review portion of this study (29-35). Table 5 outlines the study design, study period, vaccines under observation, study population, and the frequency and demographics of myocarditis or pericarditis cases within each study. All observational designs in all populations were considered, therefore meta-analyses or pooling of results were not appropriate.

Studies were assessed for quality using the most appropriate CASP checklist (36). One reviewer assessed quality, using questions within the checklist. All studies were considered of sufficient quality to be included (data not shown).

Results of all studies were consistent. Where reported, males represented 80-100% of the study populations (Table 5). The age ranges of myocarditis cases varied, however in three of the four studies where ages were reported, cases appeared to occur most frequently in younger patients (under the age of 40 years) (32, 34, 35). In the fourth study, post-mortem examination revealed myocarditis as the cause of death in one 65-year-old male (33). This patient had pre-existing cardiac disease, therefore it was not conclusively determined whether exposure to the vaccine resulted in this patient's death (33).

4.0 Discussion

There have been a small number of reports of myocarditis and pericarditis following exposure to mRNA COVID-19 vaccines in each database examined, considering the number of people who have received a COVID-19 vaccine in each region. In all spontaneous reporting systems and for both mRNA vaccines, the reporting rate of myocarditis was higher than that of pericarditis. This may be true, or it may also reflect that the diagnosis of myocarditis is relatively more straightforward. In the UK and EU/EEA, reporting rates of myocarditis and pericarditis were higher following Spikevax compared with those for Comirnaty. However, the opposite was observed for the US. A full dose of Spikevax used for first and second doses contains 100 micrograms of mRNA nucleotides, whereas a full dose of Comirnaty contains 30 micrograms of the mRNA material (10, 11). This is one possible reason for the higher reporting rate of myocarditis and pericarditis observed for Spikevax in the UK population. A half dose of Spikevax is used for third vaccination doses; this still contains more genetic material than Comirnaty (10). Therefore, it will become increasingly important as more people receive third booster doses of mRNA COVID-19 vaccines to monitor the frequency and severity of myocarditis and pericarditis following exposure to these vaccines.

The UK had the highest reporting rate for both myocarditis and pericarditis following mRNA vaccines, particularly for events following Spikevax. Reporting rates for the US and EU/EEA regions were similar for each event following each vaccine. It is possible that the UK and EU/EEA have stronger spontaneous reporting systems compared with the US, which may explain the higher reporting rates observed for this population. The frequency of events noted by regulators, the World Health Organisation, and in the vaccines' summaries of product characteristics (SmPC) suggest that myocarditis and pericarditis

are very rare, occurring in less than one in 10,000 vaccine doses administered (2, 3, 7, 12, 13). Our calculated reporting rates for myocarditis and pericarditis following mRNA vaccines in each of the UK, US, and EU/EEA were consistent with this. However, underreporting of the events to regulators is possible, therefore it may be that the events of myocarditis and pericarditis are 'rare' events (more frequent than 1/10,000) rather than 'very rare' (less frequent than 1/10,000) events as suggested. In October 2021, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency announced a plan to review the risk of myocarditis and pericarditis following mRNA vaccines (37). It is therefore possible that updates to the vaccines' SmPC will be required once this review is complete.

When examining the demographics of vaccinees who had reported myocarditis or pericarditis following mRNA vaccines, both events appear to more commonly affect males compared with females, particularly amongst vaccinees of younger age categories (Tables 2-4). This is consistent with early reports surrounding these events, where it was suggested that younger males appear at higher risk of myocarditis and pericarditis following mRNA vaccines (4). Demographic data was available for VAERS and EudraVigilance populations; in these databases results were similar with more than 70% of myocarditis and more than 50% of pericarditis events reported in males (Tables 2 and 4). These results are consistent with results of pharmacoepidemiological studies in the published literature; in the studies where sex was reported, more than 80% of patients were male and most patients were under the age of 40 years (Table 5) (30-35). This is an interesting finding, as it has been previously suggested that over 70% of reports to VAERS involve females (31). It is possible that the event was missed or misclassification occurred in older adults, particularly in older individuals in the three populations of interest who were vaccinated prior to the signal emerging. It is also possible that some of the symptoms of myocarditis and pericarditis, for example chest pain and breathlessness, were attributed to other cardio-respiratory conditions in older people. Nonetheless, it is known that most cases of myocarditis (any cause) occur in young adults, with males more commonly affected than females; this supports the results observed in this study (38, 39). Alternatively, vaccine roll-out in each of the regions may have affected the results observed in some of the countries; in the UK, mRNA vaccines were more frequently used in younger age groups, while older vaccinees may have been more likely to receive an adenovirus vector vaccine.

Data on vaccine dose were only available from the VAERS database. Most cases reported to VAERS to be reported following a second dose of vaccine (Tables 3a and 3b). This is consistent with the early signal which emerged in Israel, where 121 of the 148 reported cases of myocarditis occurred around the time of the second dose of COVID-19 vaccine (4). Furthermore, similar results were observed by Hajjo et al., who found only a very small number of events occurring after a third dose in their analysis of VAERS data (40).

Pharmacoepidemiological studies identified by systematic review (Table 5) were consistent with results found in spontaneously data from VAERS and EudraVigilance (Tables 2-5). Young males more frequently reported myocarditis in each of these studies and found in our analysis of spontaneous reporting data. Furthermore, reports were more frequent following a second dose of mRNA vaccine.

Myocarditis has been observed historically following vaccination, including after smallpox, influenza, and hepatitis B vaccines; prior to COVID-19, 0.1% of reports to

VAERS between 1990 and 2018 had been in relation to myopericarditis (5). Furthermore, myocarditis is known to occur after a range of viral infections, including coronaviruses which cause Middle East Respiratory Syndrome (MERS) and COVID-19, with viral infection the most common cause of myocarditis (41-43). This study provides evidence that younger vaccinees more frequently report myocarditis and pericarditis following mRNA COVID-19 vaccines compared with older vaccinees, and reports are more frequent following the second dose. Results were consistent between each of the three data sources used. This is an important finding, because as vaccination programmes around the world progress, rates of myocarditis and pericarditis are likely to increase. The effect of booster vaccinations with mRNA COVID-19 vaccines on the development of myocarditis and pericarditis is largely unknown. Furthermore, mRNA COVID-19 vaccines (particularly Spikevax) will be supplied to the COVAX initiative for distribution throughout low- and middle-income countries, where diagnostic imaging and access to healthcare is more difficult (44, 45). Regulatory authorities should continue to monitor the effect of mRNA vaccination might have on the heart in the populations for which they are responsible. The proportions of young people are higher in low- and middle-income countries' populations compared to high income countries. Issuing diagnostic criteria and treatment protocols for myocarditis and pericarditis with mRNA COVID-19 vaccines that take into consideration the capabilities of the local healthcare system.

4.1 Limitations

Vaccination policies in the three regions may have biased the results towards a higher number of adverse events reports myocarditis and pericarditis from younger vaccinees compared with older vaccinees. In each of these regions, younger people were more likely to have received mRNA vaccines, which may have contributed to higher reporting rates of myocarditis and pericarditis in younger vaccinees. The frequency of reported events per age group was presented as a crude number, and reporting rates could only be calculated as an overall estimate rather than stratified by age; based on the data available for vaccinations administered, it was not possible to determine the proportion of all vaccinees per age group who reported an event of myocarditis or pericarditis. This is very important, because it is likely that the reporting rate of myocarditis and pericarditis with mRNA COVID-19 vaccines will be higher in young people and even higher in young men if the reporting rates are stratified by age and sex. The regulatory authorities and Marketing Authorisations Holders (MAHs) need to follow up reports of these conditions with reporters to obtain as much information and make this information available publicly. Myocarditis and pericarditis following mRNA COVID-19 vaccines is an area which requires further research.

The data sources for this study were spontaneous reporting systems of the UK, US, and EEA. All spontaneous reporting systems have well-known limitations including missing information, and reporting bias caused by publicity surrounding a particular adverse event. (46). Misclassification of myocarditis and pericarditis is also possible particularly before these events attracted publicity or among older age groups. Under-reporting is a major limitation of spontaneous reporting; even with the intense publicity and global attention on COVID-19 vaccine safety, it is possible that not all cases are reported to regulatory authorities (47, 48). Furthermore, a report to spontaneous reporting systems indicates suspicion that the event was associated with the vaccine, it does not confirm that the vaccine caused the event (3, 46). Further assessment is required to determine

causality for each report. Finally, it is not possible to estimate incidence rates using spontaneous reports, and there is no unvaccinated comparison group (46).

Using publicly available data introduced some challenges, as the level of detail available was limited and varied between data sources. The MHRA does not publish detail on each of the reported events, including demographics of the vaccinees in which reported events occur. Furthermore, data on the vaccine dose on which the reported events of myocarditis and pericarditis occurred were only available for the US VAERS population. Information contained within individual reports is not routinely made available, however these comprise important clinical information that would allow better understanding of each case. Such details should be made publicly available. Better transparency is needed to allow more robust research using spontaneous reporting to be undertaken.

Due to the limited published research into myocarditis and pericarditis following mRNA COVID-19 vaccines, we included all pharmacoepidemiological study designs (except case reports and case series) and considered all study populations and all study periods for inclusion. The purpose of systematically reviewing the literature was to determine whether results from our analyses of spontaneous reports were consistent with other evidence currently available. Due to the heterogenous nature of the included studies, no pooling of data, syntheses, or meta-analyses could be completed. It should be noted that there were no formal assessments of publication bias during the systematic literature review. However, a CASP checklist was completed for each included study, which deemed the research to be of sufficient quality for inclusion. Nonetheless, each study had limitations which should be considered when interpreting their results. The possibility of publication bias was not formally analysed.

Further pharmacoepidemiological studies are urgently needed to address many of the limitations of spontaneous reporting in understanding myocarditis and pericarditis following mRNA COVID-19 vaccines including more accurate estimates of the frequency, better understanding of the clinical course and the effects of these on quality of life. It is also important to compare the incidence and characteristics of these events with recipients of other non-mRNA COVID-19 vaccines and unvaccinated people. However, these studies will take time to be conducted.

5.0 Conclusions

This study adds to existing evidence that younger vaccinees more frequently report myocarditis and pericarditis following mRNA COVID-19 vaccines compared with older vaccinees, and reports are more frequent following the second dose. These events are very rare or possibly rare according to the estimated reporting rates from spontaneous adverse reactions. The events were more frequently reported amongst males, and most reports came from vaccinees aged under 30 years. The clinical course of these events is typically mild, with full recovery in most cases.

The study brings together spontaneously reported adverse event data from three regions. Consistencies in the reporting rates and trends of myocarditis and pericarditis within the three data sources utilised suggest that results may be generalisable to other populations in which mRNA vaccines are used. However, limitations of the data sources used and biases which may have affected results should be considered. It is important that regulatory authorities continue to monitor the effects of mRNA vaccines on the

heart, particularly as vaccine programmes progress to include younger vaccinees in many parts of the world. Myocarditis and pericarditis following mRNA COVID-19 vaccines is an area which requires further research, especially in children and adolescents and following a third (booster) dose. Pharmacoepidemiological studies are urgently needed to address many of the limitations of spontaneous reporting in understanding myocarditis and pericarditis following mRNA Covid-19 vaccines including more accurate estimates of frequency, a better understanding of the clinical course, and the effects on quality of life. However, they will take time to be conducted.

Declarations

Transparency statement

The manuscript's guarantor affirms that the manuscript is an honest, accurate, and transparent account of the study being reported, and that no important aspects of the study have been omitted.

Ethics approval

Ethics approval was not required.

Funding

No external funding was received for the preparation of this manuscript.

Conflicts of interest

All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: The Drug Safety Research Unit (DSRU) is a registered independent charity (No. 327206) associated with the University of Portsmouth. The DSRU receives donations and grants from pharmaceutical companies; however, the companies have no control over the conduct or publication of its studies. The DSRU has received grants to conduct unconditional studies on the Oxford/AstraZeneca COVID-19 vaccine and is in negotiations to receiving grants for conducting CPRD studies for Pfizer, Moderna, and Janssen COVID-19 vaccines. The DSRU has conducted benefit-risk studies on products for COVID-19, including remdesivir, lopinavir/ritonavir, chloroquine and hydroxychloroquine, and convalescent plasma. Professor Shakir is the principal investigator for an active surveillance study for the Oxford/AstraZeneca vaccine, but this assessment is unrelated to this study. Professor Shakir has been a member of Data Safety Monitoring Boards for Ipsen, Biogen, and Diurnal. None of these companies have any involvement with COVID-19 vaccines. Professor Shakir was invited by AstraZeneca to advise on the events of thrombosis with thrombocytopenia with the COVID-19 vaccine and to be a member of an advisory committee on a safety study of the Oxford/AstraZeneca vaccine in Europe. Samantha Lane and Alison Yeomans have no conflicts of interest with regard to this study.

Patient and public involvement

Patients and the public were not consulted during the course of this study.

Authors' contributions

SL was responsible for data acquisition, analyses, and interpretation. SL, AY, and SS were responsible for study conception, drafting and reviewing the manuscript, and approval of the final version for publication.

Data sharing

CASP checklists for assessing quality of each study included in systematic review are available on request.

References

1. Centers for Disease Prevention and Control. Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination 2021 [updated 23 June 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html.
2. COVID-19 mRNA Vaccines Comirnaty and Spikevax: risk of myocarditis and pericarditis [press release]. 19 July 2021.
3. Medicines & Healthcare products Regulatory Agency. Coronavirus vaccine - weekly summary of Yellow Card reporting. 2021.
4. Surveillance of Myocarditis (Inflammation of the Heart Muscle) Cases Between December 2020 and May 2021 (Including) [press release]. 02 June 2021.
5. Bozkurt B, Kamat I, Hotez PJ. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021;144(6):471-84.
6. Willame C, Dodd C, Gini R, Duran-Salinas C, Ehrenstein V, Thomsen RM, et al. Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccine March 2021 [Available from: http://www.encepp.eu/phact_links.shtml.
7. COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS): updated guidance regarding myocarditis and pericarditis reported with COVID-19 mRNA vaccines [press release]. 09 July 2021.
8. Leshem E, Wilder-Smith A. COVID-19 vaccine impact in Israel and a way out of the pandemic. The Lancet. 2021;397(10287):1783-5.
9. BioNTech-Pfizer. Comirnaty concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified) 2021 [updated 22 July 2021. Available from: https://www.medicines.org.uk/emc/product/12740/smpc.
10. European Medicines Agency. Spikevax (previously COVID-19 Vaccine Moderna): EPAR - Product information. 2021.
11. European Medicines Agency. Comirnaty: EPAR - Product Information. 2021.
12. Medicines & Healthcare products Regulatory Agency. Summary of Product Characteristics for COVID-19 Vaccine Moderna 2021 [updated 25 June. Available from: https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna/information-for-healthcare-professionals-on-covid-19-vaccine-moderna.
13. Medicines & Healthcare products Regulatory Agency. Summary of Product Characteristics for COVID-19 Vaccine Pfizer/BioNTech 2021 [updated 11 August 2021. Available from: https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/summary-of-product-characteristics-for-covid-19-vaccine-pfizerbiontech.
14. U.S. Food and Drug Administration (FDA). Fact sheet for healthcare providers administering vaccine (vaccination providers) Emergency Use Authorization (EUA) of the Moderna COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19). 2021.
15. U.S. Food and Drug Administration (FDA). Fact sheet for healthcare providers administering vaccine (vaccination providers) Emergency Use Authorization (EUA) Of The Pfizer-BioNTech COVID-19 Vaccine To Prevent Coronavirus Disease 2019 (COVID-19). 2021.
16. NHS. Coronavirus (COVID-19) vaccine for children aged 12 to 15 2021 [updated 1 November 2021. Available from: https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine-for-children-aged-12-to-15/.
17. NHS. Who can get a coronavirus (COVID-19) vaccine 2021 [updated 5 November 2021. Available from: https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/who-can-get-the-vaccine/.
18. European Medicines Agency. COVID-19: latest updates 2021 [updated 10 November 2021. Available from: https://www.ema.europa.eu/en/human-

regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-latest-updates.
19. EMA starts evaluating use of COVID-19 vaccine Spikevax in children aged 6 to 11 [press release]. 10 November 2021 2021.
20. EMA starts evaluating use of COVID-19 vaccine Comirnaty in children aged 5 to 11 [press release]. 18 October 2021 2021.
21. FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age [press release]. 29 October 2021 2021.
22. Hause AM, Gee J, Baggs J, Abara WE, Marquez P, Thompson D, et al. COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021. 2021 6 August 2021.
23. Jenco M. CDC confirms 226 cases of myocarditis after COVID-19 vaccination in people 30 and under. AAP News. 2021 10 June 2021.
24. European Medicines Agency. EudraVigilance - European Database of Suspected Adverse Drug Reaction Reports. 2021.
25. Medicines & Healthcare products Regulatory Agency. COVID-19 Moderna Vaccine Analysis Print. 2021.
26. United States Department of Health and Human Services, Department of Health and Human Services (DHHS), Public Health Service (PHS), (CDC) FaDAFCfDC. CDC WONDER Online Database. 1990 - Last Friday.
27. Centers for Disease Prevention and Control. COVID Data Tracker COVID-19 Vaccinations in the United States 2021 [updated 21 October 2021. Available from: https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total.
28. European Centre for Disease Prevention and Control. Data on COVID-19 vaccination in the EU/EEA 2021 [Available from: https://www.ecdc.europa.eu/en/publications-data/data-covid-19-vaccination-eu-eea.
29. Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Annals of the rheumatic diseases. 2021;80(10):1330-8.
30. Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. The New England journal of medicine. 2021.
31. Rose J, McCullough PA. A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products. Current problems in cardiology. 2021:101011.
32. Schauer J, Buddhe S, Colyer J, Sagiv E, Law Y, Chikkabyrappa SM, et al. Myopericarditis after the Pfizer mRNA COVID-19 Vaccine in Adolescents. The Journal of pediatrics. 2021.
33. Schneider J, Sottmann L, Greinacher A, Hagen M, Kasper HU, Kuhnen C, et al. Postmortem investigation of fatalities following vaccination with COVID-19 vaccines. International journal of legal medicine. 2021:1-11.
34. Simone A, Herald J, Chen A, Gulati N, Shen AY, Lewin B, et al. Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. JAMA internal medicine. 2021.
35. Starekova J, Bluemke DA, Bradham WS, Grist TM, Schiebler ML, Reeder SB. Myocarditis Associated with mRNA COVID-19 Vaccination. Radiology. 2021:211430.
36. Critical Appraisal Skills Programme. CASP Checklists 2021 [Available from: https://casp-uk.net/casp-tools-checklists/.
37. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 October 2021 2021 [updated 29 October 2021.

Available from: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-25-28-october-2021.
38. National Organisation for Rare Disorders. Myocarditis 2015 [Available from: https://rarediseases.org/rare-diseases/myocarditis/.
39. Golpour A, Patriki D, Hanson PJ, McManus B, Heidecker B. Epidemiological Impact of Myocarditis. J Clin Med. 2021;10(4):603.
40. Hajjo R, Sabbah DA, Bardaweel SK, Tropsha A. Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients. Vaccines. 2021;9(10).
41. Bajaj R, Sinclair HC, Patel K, Low B, Pericao A, Manisty C, et al. Delayed-onset myocarditis following COVID-19. The Lancet Respiratory Medicine. 2021;9(4):e32-e4.
42. Siripanthong B, Nazarian S, Muser D, Deo R, Santangeli P, Khanji MY, et al. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020;17(9):1463-71.
43. Arbustini E, Narula N, Giuliani L, Di Toro A. Genetic Basis of Myocarditis: Myth or Reality? Myocarditis. 2020:45-89.
44. Gavi signs agreement with Moderna to secure doses on behalf of COVAX Facility [press release]. 3 May 2021 2021.
45. Pfizer and BioNTech reach agreement with COVAX for advance purchase of vaccine to help combat COVID-19 [press release]. 22 January 2021 2021.
46. Centers for Disease Prevention and Control. Vaccine Adverse Event Reporting System (VAERS) 2021 [updated 2 July 2021. Available from: https://wonder.cdc.gov/wonder/help/vaers.html#Additional.
47. Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiology. 2021.
48. Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review. Drug safety. 2006;29(5):385-96.

Figure 1: Histogram of the age of vaccinees reporting to VAERS and EudraVigilance. (A) Reports of myocarditis to VAERS; (B) Reports of pericarditis to VAERS; (C) Reports of myocarditis to EudraVigilance; (D) Reports of pericarditis to EudraVigilance.



Table 1: Myocarditis and Pericarditis events reported Yellow Card. Datalock point 20 October 2021.

Vaccine	Myocarditis reported events	Myocarditis reports with fatal outcome	Pericarditis reported events	Pericarditis reports with fatal outcome	Total reported events	Total reports with fatal outcome
	n	n	n	n	N	N
Comirnaty (Pfizer/BioNTech)	350	1	274	1	624	2
Spikevax (Moderna)	85	0	53	0	138	0
Overall	423	1	317	1	740	2

Table 2: Myocarditis and pericarditis events reported to VAERS overall. Datalock point 21 October 2021. Percentages per age group are presented.

Age Group	Myocarditis								Pericarditis							
	Male		Female		Sex Not Specified		Total		Male		Female		Sex Not Specified		Total	
	n	%	n	%	n	%	N	%	n	%	n	%	n	%	N	%
Comirnaty																
6-17 Years	420	88.42	53	11.16	2	0.42	475	100.00	117	86.67	17	12.59	1	0.74	135	100.00
18-29 Years	320	82.90	65	16.84	1	0.26	386	100.00	168	86.15	27	13.85	0	0.00	195	100.00
30-39 Years	96	68.57	44	31.43	0	0.00	140	100.00	86	68.25	40	31.75	0	0.00	126	100.00
40-49 Years	52	57.78	38	42.22	0	0.00	90	100.00	36	43.37	47	56.63	0	0.00	83	100.00
50-59 Years	26	40.63	38	59.38	0	0.00	64	100.00	49	46.67	56	53.33	0	0.00	105	100.00
60-64 Years	8	32.00	15	60.00	2	8.00	25	100.00	16	33.33	32	66.67	0	0.00	48	100.00
65-79 Years	28	56.00	22	44.00	0	0.00	50	100.00	51	57.95	36	40.91	1	1.14	88	100.00
80+ Years	1	33.33	2	66.67	0	0.00	3	100.00	5	50.00	5	50.00	0	0.00	10	100.00
Not Specified	50	61.73	17	20.99	14	17.28	81	100.00	11	40.74	14	51.85	2	7.41	27	100.00
Total	1001	76.18	294	22.37	19	1.45	1314	100.00	539	65.97	274	33.54	4	0.49	817	100.00
Spikevax																
6-17 Years	4	80.00	1	20.00	0	0.00	5	100.00	1	100.00	0	0.00	0	0.00	1	100.00
18-29 Years	245	85.96	40	14.04	0	0.00	285	100.00	94	76.42	29	23.58	0	0.00	123	100.00
30-39 Years	91	75.21	30	24.79	0	0.00	121	100.00	45	65.22	24	34.78	0	0.00	69	100.00
40-49 Years	45	64.29	25	35.71	0	0.00	70	100.00	36	51.43	34	48.57	0	0.00	70	100.00
50-59 Years	23	53.49	19	44.19	1	2.33	43	100.00	34	53.13	30	46.88	0	0.00	64	100.00
60-64 Years	8	36.36	14	63.64	0	0.00	22	100.00	16	47.06	18	52.94	0	0.00	34	100.00
65-79 Years	19	54.29	16	45.71	0	0.00	35	100.00	30	48.39	31	50.00	1	1.61	62	100.00

80+ Years	4	57.14	3	42.86	0	0.00	7	100.00	5	38.46	8	61.54	0	0.00	13	100.00
Not Specified	18	52.94	2	5.88	14	41.18	34	100.00	6	33.33	4	22.22	8	44.44	18	100.00
Total	457	73.47	150	24.12	15	2.41	622	100.00	267	58.81	178	39.21	9	1.98	454	100.00
Overall (both mRNA vaccines)																
6-17 Years	424	88.33	54	11.25	2	0.42	480	100.00	118	86.76	17	12.50	1	0.74	136	100.00
18-29 Years	565	84.20	105	15.65	1	0.15	671	100.00	262	82.39	56	17.61	0	0.00	318	100.00
30-39 Years	187	71.65	74	28.35	0	0.00	261	100.00	131	67.18	64	32.82	0	0.00	195	100.00
40-49 Years	97	60.63	63	39.38	0	0.00	160	100.00	72	47.06	81	52.94	0	0.00	153	100.00
50-59 Years	49	45.79	57	53.27	1	0.93	107	100.00	83	49.11	86	50.89	0	0.00	169	100.00
60-64 Years	16	34.04	29	61.70	2	4.26	47	100.00	32	39.02	50	60.98	0	0.00	82	100.00
65-79 Years	47	55.29	38	44.71	0	0.00	85	100.00	81	54.00	67	44.67	2	1.33	150	100.00
80+ Years	5	50.00	5	50.00	0	0.00	10	100.00	10	43.48	13	56.52	0	0.00	23	100.00
Not Specified	68	59.13	19	16.52	28	24.35	115	100.00	17	37.78	18	40.00	10	22.22	45	100.00
Total	1458	75.31	444	22.93	34	1.76	1936	100.00	806	63.41	452	35.56	13	1.02	1271	100.00

Table 3a: Myocarditis and pericarditis events reported to VAERS following Pfizer/BioNTech COVID-19 vaccine (Comirnaty), by dose. Datalock point 21 October 2021. Percentages per age group are presented.

Age Group	Myocarditis								Pericarditis							
	Male		Female		Sex Not Specified		Total		Male		Female		Sex Not Specified		Total	
	n	%	n	%	n	%	N	%	n	%	n	%	n	%	N	%
Dose 1																
6-17 Years	78	89.66	9	10.34	0	0.00	87	100.00	21	75.00	7	25.00	0	0.00	28	100.00
18-29 Years	55	78.57	15	21.43	0	0.00	70	100.00	41	73.21	15	26.79	0	0.00	56	100.00
30-39 years	22	52.38	20	47.62	0	0.00	42	100.00	30	62.50	18	37.50	0	0.00	48	100.00
40-49 years	8	42.11	11	57.89	0	0.00	19	100.00	9	37.50	15	62.50	0	0.00	24	100.00
50-59 years	6	31.58	13	68.42	0	0.00	19	100.00	17	44.74	21	55.26	0	0.00	38	100.00
60-64 years	2	28.57	5	71.43	0	0.00	7	100.00	4	23.53	13	76.47	0	0.00	17	100.00
65-79 Years	10	52.63	9	47.37	0	0.00	19	100.00	20	64.52	11	35.48	0	0.00	31	100.00
80+ Years	0	0.00	2	100.00	0	0.00	2	100.00	2	66.67	1	33.33	0	0.00	3	100.00
Not Specified	8	53.33	6	40.00	1	6.67	15	100.00	2	50.00	2	50.00	0	0.00	4	100.00
Total	189	67.50	90	32.14	1	0.36	280	100.00	146	58.63	103	41.37	0	0.00	249	100.00
Dose 2																
6-17 Years	264	88.29	34	11.37	1	0.33	299	100.00	79	89.77	9	10.23	0	0.00	88	100.00
18-29 Years	185	83.33	36	16.22	1	0.45	222	100.00	89	91.75	8	8.25	0	0.00	97	100.00
30-39 years	56	72.73	21	27.27	0	0.00	77	0.00	47	71.21	19	28.79	0	0.00	66	100.00
40-49 years	34	59.65	23	40.35	0	0.00	57	0.00	20	43.48	26	56.52	0	0.00	46	100.00
50-59 years	15	41.67	21	58.33	0	0.00	36	0.00	25	47.17	28	52.83	0	0.00	53	100.00
60-64 years	4	44.44	5	55.56	0	0.00	9	0.00	7	33.33	14	66.67	0	0.00	21	100.00

65-79 Years	13	56.52	10	43.48	0	0.00	23	0.00	24	58.54	16	39.02	1	2.44	41	100.00
80+ Years	1	100.00	0	0.00	0	0.00	1	0.00	3	50.00	3	50.00	0	0.00	6	100.00
Not Specified	38	80.85	6	12.77	3	6.38	47	100.00	5	33.33	8	53.33	2	13.33	15	100.00
Total	610	79.12	156	20.23	5	0.65	771	100.00	299	69.05	131	30.25	3	0.69	433	100.00
Dose 3																
6-17 Years	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
18-29 Years	0	0.00	0	0.00	0	0.00	0	0.00	1	100.00	0	0.00	0	0.00	1	100.00
30-39 years	2	100.00	0	0.00	0	0.00	2	100.00	0	0.00	0	0.00	0	0.00	0	0.00
40-49 years	0	0.00	1	100.00	0	0.00	1	100.00	0	0.00	0	0.00	0	0.00	0	0.00
50-59 years	0	0.00	0	0.00	0	0.00	0	0.00	1	50.00	1	50.00	0	0.00	2	100.00
60-64 years	1	50.00	1	0.00	0	0.00	2	100.00	0	0.00	1	100.00	0	0.00	1	100.00
65-79 Years	4	100.00	0	0.00	0	0.00	4	100.00	3	100.00	0	0.00	0	0.00	3	100.00
80+ Years	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
Not Specified	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
Total	7	77.78	2	22.22	0	0.00	9	100.00	5	71.43	2	28.57	0	0.00	7	100.00
Unknown dose																
6-17 Years	78	87.64	10	11.24	1	1.12	89	100.00	17	89.47	1	5.26	1	5.26	19	100.00
18-29 Years	80	85.11	14	14.89	0	0.00	94	100.00	37	90.24	4	9.76	0	0.00	41	100.00
30-39 years	16	84.21	3	15.79	0	0.00	19	100.00	9	75.00	3	25.00	0	0.00	12	100.00
40-49 years	10	76.92	3	23.08	0	0.00	13	100.00	7	53.85	6	46.15	0	0.00	13	100.00
50-59 years	5	55.56	4	44.44	0	0.00	9	100.00	6	50.00	6	50.00	0	0.00	12	100.00
60-64 years	1	14.29	4	57.14	2	28.57	7	100.00	5	55.56	4*	44.44	0	0.00	9	100.00
65-79 Years	1	25.00	3	75.00	0	0.00	4	100.00	4	30.77	9	69.23	0	0.00	13	100.00
80+ Years	0	0.00	0	0.00	0	0.00	0	100.00	0	0.00	1	100.00	0	0.00	1	100.00
Not Specified	0	0.00	0	0.00	0	0.00	0	100.00	4	50.00	4	50.00	0	0.00	8	100.00

Total	191	81.28	41	17.45	3	1.28	235	100.00	89	69.53	38	29.69	1	0.78	128	100
*Includes 2 reported events occurring after reported 5 doses																

Table 3b: Myocarditis and pericarditis events reported to VAERS following Moderna COVID-19 vaccine (Spikevax), by dose. Datalock point 21 October 2021. Percentages per age group are presented.

Age Group	Myocarditis								Pericarditis							
	Male		Female		Sex Not Specified		Total		Male		Female		Sex Not Specified		Total	
	n	%	n	%	n	%	N	%	n	%	n	%	n	%	N	%
Dose 1																
6-17 Years	1	100.00	0	0.00	0	0.00	1	0.00	0	0.00	0	0.00	0	0.00	0	0.00
18-29 Years	61	83.56	12	16.44	0	0.00	73	100.00	25	67.57	12	32.43	0	0.00	37	100.00
30-39 years	34	69.39	15	30.61	0	0.00	49	100.00	13	52.00	12	48.00	0	0.00	25	100.00
40-49 years	11	55.00	9	45.00	0	0.00	20	100.00	16	53.33	14	46.67	0	0.00	30	100.00
50-59 years	12	57.14	8	38.10	1	4.76	21	100.00	10	47.62	11	52.38	0	0.00	21	100.00
60-64 years	4	30.77	9	69.23	0	0.00	13	100.00	4	40.00	6	60.00	0	0.00	10	100.00
65-79 Years	8	50.00	8	50.00	0	0.00	16	100.00	7	38.89	10	55.56	1	5.56	18	100.00
80+ Years	2	66.67	1	33.33	0	0.00	3	100.00	0	0.00	4	100.00	0	0.00	4	100.00
Not Specified	14	70.00	0	0.00	6	30.00	20	100.00	3	37.50	3	37.50	2	25.00	8	100.00
Total	147	68.06	62	28.70	7	3.24	216	100.00	78	50.98	72	47.06	3	1.96	153	100.00
Dose 2																
6-17 Years	2	100.00	0	0.00	0	0.00	2	100.00	1	100.00	0	0.00	0	0.00	1	100.00
18-29 Years	131	85.06	23	14.94	0	0.00	154	100.00	54	83.08	11	16.92	0	0.00	65	100.00
30-39 years	40	81.63	9	18.37	0	0.00	49	100.00	25	71.43	10	28.57	0	0.00	35	100.00
40-49 years	23	60.53	15	39.47	0	0.00	38	100.00	15	48.39	16	51.61	0	0.00	31	100.00
50-59 years	9	56.25	7	43.75	0	0.00	16	100.00	18	52.94	16	47.06	0	0.00	34	100.00
60-64 years	3	50.00	3	50.00	0	0.00	6	100.00	7	43.75	9	56.25	0	0.00	16	100.00

65-79 Years	11	64.71	6	35.29	0	0.00	17	100.00	18	51.43	17	48.57	0	0.00	35	100.00
80+ Years	1	50.00	1	50.00	0	0.00	2	100.00	4	50.00	4	50.00	0	0.00	8	100.00
Not Specified	2	28.57	1	14.29	4	57.14	7	100.00	2	50.00	1	25.00	1	25.00	4	100.00
Total	222	76.29	65	22.34	4	1.37	291	100.00	144	62.88	84	36.68	1	0.44	229	100.00
Dose 3																
6-17 Years	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
18-29 Years	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
30-39 years	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	1	100.00	0	0.00	1	100.00
40-49 years	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
50-59 years	0	0.00	3	100.00	0	0.00	3	100.00	0	0.00	0	0.00	0	0.00	0	0.00
60-64 years	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
65-79 Years	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
80+ Years	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
Not Specified	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
Total	0	0.00	3	100.00	0	0.00	3	100.00	0	0.00	1	100.00	0	0.00	1	100.00
Unknown dose																
6-17 Years	1	50.00	1	50.00	0	0.00	2	100.00	0	0.00	0	0.00	0	0.00	0	0.00
18-29 Years	53	91.38	5	8.62	0	0.00	58	100.00	15	71.43	6	28.57	0	0.00	21	100.00
30-39 years	17	73.91	6	26.09	0	0.00	23	100.00	7	87.50	1	12.50	0	0.00	8	100.00
40-49 years	11	91.67	1	8.33	0	0.00	12	100.00	5	55.56	4	44.44	0	0.00	9	100.00
50-59 years	2	40.00	3	60.00	0	0.00	5	100.00	6	66.67	3	33.33	0	0.00	9	100.00
60-64 years	1	33.33	2	66.67	0	0.00	3	100.00	5	62.50	3	37.50	0	0.00	8	100.00
65-79 Years	0	0.00	2	100.00	0	0.00	2	100.00	5	55.56	4	44.44	0	0.00	9	100.00
80+ Years	1	50.00	1	50.00	0	0.00	2	100.00	1	100.00	0	0.00	0	0.00	1	100.00
Not Specified	2	28.57	1	14.29	4	57.14	7	100.00	1	20.00	0	0.00	4	80.00	5	100.00

Total	88	77.19	22	19.30	4	3.51	114	100.00	45	64.29	21	30.00	4	5.71	70	100.00

Table 4: Myocarditis and pericarditis events reported to EudraVigilance for the European Economic Area. Datalock point 21 October 2021. Percentages per age group are presented.

Age Group	Myocarditis								Pericarditis							
	Male		Female		Sex Not Specified		Total		Male		Female		Sex Not Specified		Total	
	n	%	n	%	n	%	N	%	n	%	n	%	n	%	N	%
Comirnaty																
12-17 Years	256	85.91	37	12.42	5	1.68	298	100.00	44	61.11	28	38.89	0	0.00	72	100.00
18-64 Years	1251	73.89	431	25.46	11	0.65	1693	100.00	606	49.67	610	50.00	4	0.33	1220	100.00
65-85 Years	69	51.49	65	48.51	0	0.00	134	100.00	109	57.37	81	42.63	0	0.00	190	100.00
Over 85 Years	6	50.00	6	50.00	0	0.00	12	100.00	14	63.64	8	36.36	0	0.00	22	100.00
Not Specified	57	69.51	21	25.61	4	4.88	82	100.00	13	52.00	12	48.00	0	0.00	25	100.00
Total	1639	73.86	560	25.24	20	0.90	2219	100.00	786	51.41	739	48.33	4	0.26	1529	100.00
Spikevax																
12-17 Years	29	100.00	0	0.00	0	0.00	29	100.00	4	100.00	0	0.00	0	0.00	4	100.00
18-64 Years	540	83.20	106	16.33	3	0.46	649	100.00	163	58.63	112	40.29	3	1.08	278	100.00
65-85 Years	10	50.00	10	50.00	0	0.00	20	100.00	16	43.24	21	56.76	0	0.00	37	100.00
Over 85 Years	0	0.00	1	100.00	0	0.00	1	100.00	0	0.00	2	100.00	0	0.00	2	100.00
Not Specified	5	83.33	1	16.67	0	0.00	6	100.00	3	60.00	2	40.00	0	0.00	5	100.00
Total	584	82.84	118	16.74	3	0.43	705	100.00	186	57.06	137	42.02	3	0.92	326	100.00
Overall (both mRNA vaccines)																
12-17 Years	285	87.16	37	11.31	5	1.53	327	100.00	48	63.16	28	36.84	0	0.00	76	100.00
18-64 Years	1791	76.47	537	22.93	14	0.60	2342	100.00	769	51.34	722	48.20	7	0.47	1498	100.00
65-85 Years	79	51.30	75	48.70	0	0.00	154	100.00	125	55.07	102	44.93	0	0.00	227	100.00

Over 85 Years	6	46.15	7	53.85	0	0.00	13	100.00	14	58.33	10	41.67	0	0.00	24	100.00
Not Specified	62	70.45	22	25.00	4	4.55	88	100.00	16	53.33	14	46.67	0	0.00	30	100.00
Total	2223	76.06	678	23.19	23	0.79	2924	100.00	972	52.40	876	47.22	7	0.38	1855	100.00

Table 5: Details of each study identified by systematic review which met the inclusion criteria.

Author/Citation	Study period	Study design	Vaccine	Population	Condition	Cases	Age	Sex (% who are male)	Dose
Furer et al. **(29)**	12/2020 – 03/2021	Multicentre cohort study	Comirnaty (2 doses)	Adults with autoimmune inflammatory rheumatic diseases (n=670) and healthy controls (n=121) at the Rheumatology Departments of Tel Aviv Sourasky, Carmel, and Hadassah Medical Center, Israel	Pericarditis	1 case of pericarditis in autoimmune diseases group	NR	NR	2
Mevorach et al. **(30)**	20/12/2020 – 31/5/2021	Retrospective review of medical records	Comirnaty	Israeli residents included in wider vaccine safety surveillance	Myocarditis	19 117	NR	89.5% 86.3%	1 2
Rose et al. **(31)**	Up to 9/7/2021	Analysis of VAERS data	Comirnaty, Spikevax, Johnson & Johnson	Adolescents (aged 12-15 years) and adults reporting to VAERS	Myocarditis	559	NR	80%	NR*
Schauer et al. **(32)**	1/4/2021 – 21/6/2021	Retrospective review of	Comirnaty (2 doses)	Adolescents aged 12-17 years,	Myopericarditis	13	Median 15	92.3%	2

		medical records		admitted to Seattle Children's Hospital, Washington State, US			years		
Schneider et al. **(33)**	11/3/2021 – 9/6/2021	Postmortem investigation	Any COVID-19 vaccine	Catchment of Bielefeld, Detmold & Münster Public Prosecutor's Offices, Germany	Myocarditis	1	65 years old	100%	1 dose of Pfizer
Simone et al. **(34)**	14/12/2020 – 20/7/2021	Cohort	At least one dose of Comirnaty or Spikevax	Kaiser Permanente (healthcare provider) Southern California members	Myocarditis	8 (Comirnaty) 7 (Spikevax)	18-40 years	100%	13 cases occurred following second dose
Starekova et al. **(35)**	1/1/2021 – 25/5/2021	Retrospective review of medical records	Comirnaty or Spikevax (2 doses)	Admissions to University of Wisconsin hospital	Myocarditis	5	17-38 years	80%	2

NR = Not Reported
*71% of all reports following a second vaccine dose involved Comirnaty